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Purpose: Cyclooxygenase (COX)-2 and matrix metalloproteinase (MMP)-9 play a 
key role in the pathogenesis of in-stent restenosis. We investigated the effect of a 
short-term therapy of celecoxib, a COX-2 inhibitor, with or without doxycycline, an 
MMP inhibitor, after coronary stenting on inflammatory biomarkers and neointimal 
hyperplasia. Materials and Methods: A total of 75 patients (86 lesions) treated with 
bare metal stents were randomized into three groups: 1) combination therapy (200 
mg celecoxib and 20 mg doxycycline, both twice daily), 2) celecoxib (200 mg twice 
daily) only, and 3) non-therapy control. Celecoxib and doxycycline were adminis-
tered for 3 weeks after coronary stenting. The primary endpoint was neointimal vol-
ume obstruction by intravascular ultrasound (IVUS) at 6 months. The secondary 
endpoints included clinical outcomes, angiographic data, and changes in blood levels 
of inflammatory biomarkers. Results: Follow-up IVUS revealed no significant dif-
ference in the neointimal volume obstruction among the three treatment groups. 
There was no difference in cardiac deaths, myocardial infarctions, target lesion re-
vascularization or stent thrombosis among the groups. Blood levels of high-sensitivi-
ty C-reactive protein, soluble CD40 ligand, and MMP-9 varied widely 48 hours and 
3 weeks after coronary stenting, however, they did not show any significant differ-
ence among the groups. Conclusion: Our study failed to demonstrate any beneficial 
effects of the short-term therapy with celecoxib and doxycycline or with celecoxib 
alone in the suppression of inflammatory biomarkers or in the inhibition of neointi-
mal hyperplasia. Large scale randomized trials are necessary to define the role of an-
ti-inflammatory therapy in the inhibition of neointimal hyperplasia.   
Key Words:    Celecoxib, coronary artery disease, coronary stent, neointimal hyper-
plasia, inflammation
INTRODUCTION
Inflammatory reactions occur early after coronary stent implantation and play an 
important role in the pathogenesis of neointimal hyperplasia.1 After stenting, T Combined Therapy of Celecoxib and Doxycycline and Neointimal Hyperplasia 
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(>50% luminal narrowing on coronary angiogram) with a ref-
erence vessel diameter approximately 2.75-4.25 mm and a le-
sion length <28 mm. The following exclusion criteria were 
used: chronic inflammatory disease; autoimmune disease, 
acute or chronic infection; severe congestive heart failure 
(New York Heart Association classification >II); left ventricle 
ejection fraction <30%; hemodynamic instability; clinically 
significant hemorrhagic episode; warfarin use; hepatic dys-
function (SGOT, SGPT, Bilirubin twice the upper normal lim-
it); active peptic ulcer disease; contraindications to or history 
of allergy to aspirin, clopidogrel or celecoxib; expected sur-
vival of less than 2 years because of medical conditions; preg-
nancy or desire to become pregnant; chronic total occlusion; 
saphenous vein graft lesion; or overlapped stenting. Patients 
already taking any COX-2 inhibitors or any non-steroidal an-
ti-inflammatory drugs were also excluded. All patients pro-
vided written informed consent, and the study was approved 
by the institutional ethics committee. The study protocol was 
in accordance with the Declaration of Helsinki. 
Coronary intervention  
All patients received a daily dose of 100 mg aspirin and 75 
mg clopidogrel for ≥3 days or a loading dose of 200 mg as-
pirin and 300 mg clopidogrel before the procedure.  A bolus 
of 100 U/kg heparin was administered after sheath inser-
tion, and supplemental doses were given subsequently to 
maintain an activated clotting time >300 seconds. Balloon 
predilation was performed in all patients prior to stent im-
plantation. For coronary stenting, only bare metal stents 
(Multi-Link Vision®, Guidant, Indianapolis, IN, USA) were 
used. After stent implantation, patients continued to daily 
receive aspirin (100 mg) indefinitely and clopidogrel (75 
mg) daily for at least 6 weeks. 
Follow-up 
Patients were clinically followed at 1, 3, and 6 months. Pa-
tients were asked specific questions about major cardiac ad-
verse events and the development of angina, according to 
the Canadian Cardiovascular Society classification of stable 
angina. Follow-up coronary angiographic and intravascular 
ultrasound (IVUS) evaluations were performed 6 months 
after the initial procedure or earlier if symptoms suggestive 
of coronary restenosis developed before that time.
Quantitative coronary angiography   
Angiographic images were obtained in two orthogonal 
views after intracoronary administration of 200 μg nitro-
cells, macrophages, and smooth muscle cells are recruited 
to the implantation site; and this local inflammatory re-
sponse is thought to correlate with restenosis.2 Cyclooxy-
genase (COX) is the principal enzyme involved in the pro-
duction of prostaglandins, which are induced by tissue 
injury and implicated in the inflammatory response.3 The 
COX-2 isoenzyme is expressed in macrophages, smooth 
muscle, and endothelial cells of human atherosclerotic 
plaques, and is thought to promote neointimal growth after 
stent implantation.4 Matrix metalloproteinase (MMP) is an 
another important enzyme that has been implicated in the 
pathogenesis of restenosis. The activation of MMP has been 
shown to contribute to neointimal hyperplasia after vascu-
lar injury by controlling extracellular matrix degradation 
and facilitating intimal remodeling.5,6 Although results of 
animal studies are conflicting,7-9 a recent clinical trial showed 
that prolonged inhibition of COX-2 with celecoxib was ef-
fective in reducing restenosis.10 However, concerns about 
the safety of COX-2 inhibitors in terms of increased throm-
bosis and elevated blood pressure remain,11,12 and long-term 
use of COX-2 inhibitors in patients with cardiovascular dis-
ease is still not generally favored. Doxycycline, a derivative 
of tetracycline, is a nonspecific MMP inhibitor that has been 
shown to reduce neointimal hyperplasia in animal models.13 
However, no clinical trials have been carried out on the ef-
fect of doxycycline on restenosis after coronary stenting. In 
the present study, we investigated whether short-term ad-
ministration of celecoxib with or without inhibition of MMP 
using doxycline in the early phase after coronary stent im-
plantation could effectively reduce neointimal hyperplasia.  
MATERIALS AND METHODS
　　　
Study design and population 
The present study was designed as a prospective, open-label, 
randomized single-center trial with three treatment groups: 
combination therapy (group I), celecoxib only (group II), and 
non-therapy control (group III). For 3 weeks after coronary 
stenting, patients in group I were given celecoxib (200 mg) 
and doxycycline (20 mg) twice daily; those in group II re-
ceived celecoxib 200 mg twice daily; and those in group III 
received neither.  A total of 75 patients were enrolled at Sever-
ance Cardiovascular Hospital, Yonsei University Health Sys-
tem, from September 2004 to January 2006. Inclusion criteria 
were as follows: typical angina pectoris or documented myo-
cardial ischemia and significant coronary artery stenosis Won Ho Kim, et al.
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days and 3 weeks after PCI. High-sensitivity C-reactive pro-
tein (hsCRP) and MMP-9 in serum were measured using a 
standardized enzyme-linked immunosorbent assay (ELISA; 
R&D systems). Serum was separated from whole blood by 
centrifugation (1,000×g for 15 min) and stored at -70°C prior 
to assay. The concentration of soluble CD40 ligand in plas-
ma, obtained from EDTA-treated blood samples as described 
for serum, was quantified by ELISA (BioSource). 
Study endpoints
The primary study endpoint was neointimal volume ob-
struction on IVUS at 6 months. The secondary endpoints 
were changes in blood levels of inflammatory biomarkers 
and angiographic late loss, binary restenosis rate, and major 
adverse cardiac events, including cardiac deaths, non-fatal 
myocardial infarctions, and target vessel revascularization.
Statistical analysis
The sample size was calculated based on a two-sample and 
two-sided test. Previous studies showed that bare metal stents 
have a neointimal volume obstruction of approximately 30% 
with a standard deviation of 10% at 6 to 9 months.14-16 We 
hypothesized that effective inhibition of neointimal hyper-
sia by administration of COX-2 inhibitor with or without 
MMP inhibitor could achieve a neointimal volume obstruc-
tion of about 20%. Based on an alpha level of 0.05, statisti-
cal power of 80%, and a drop-out rate of 30%, at least 23 
patients were required for each group.
All analyses were performed using the SAS statistical pack-
age version 9.1.3. Categorical variables were expressed as 
percent and were compared using chi-square tests; when the 
expected cell number was <5, Fisher exact tests were used. 
Continuous data were expressed as mean±SD and were com-
pared using ANOVAs. For all tests, a two-tailed p-value <0.05 
was considered significant. 
 
RESULTS
 
Patient population 
Between September 2004 and January 2006, 75 patients 
with 86 lesions were randomized into three groups: group I 
(combination therapy) contained 25 patients with 26 le-
sions; group II (celcoxib only) contained 25 patients with 
28 lesions; and group II (control) contained 25 patients with 
32 lesions. The clinical and angiographic characteristics of 
the patients assigned to the three treatment groups were not 
glycerin. Follow-up coronary angiographic images with the 
same view as those in pre- and post-PCI angiography were 
used for analyses. Quantitative angiography analysis was 
performed using an offline system (CMS, Medis Medical 
Imaging System, Nuenen, the Netherlands) by experienced 
technicians who were blinded to the patients’ clinical data. 
The minimal luminal diameter (MLD) of treated coronary 
segments, reference diameter, percent diameter stenosis, 
and lesion length were measured. The angiographic end 
points were binary restenosis rate defined as an in-stent ste-
nosis >50% at 6-month follow-up coronary angiography 
and late loss defined as the MLD after the procedure minus 
the MLD at 6-month follow-up.
IVUS evaluations
IVUS was evaluated after coronary stenting and at 6-month 
follow-up using a 2.5 F Atlantis SR Pro Imaging 40 MHz 
catheter (Boston Scientific, Santa Clara, CA, USA) with an 
automatic motorized 0.5 mm/s pullback. The coronary seg-
ment was examined by IVUS beginning 5 mm distal to and 
extending 5 mm proximal to the stented segment. All IVUS 
images were obtained after intracoronary administration of 
nitroglycerin (200 μg) and recorded on s-VHS tape or com-
pact disk for offline analysis. Quantitative analysis of IVUS 
was performed using commercially available planimetry 
software (Echoplaque 2; INDEC Systems, Inc., Mountain 
View, CA, USA). IVUS measurements were made at 1-mm 
intervals. Stent and lumen areas were manually traced, and 
neointimal area was computed as stent minus lumen area. 
Proximal and distal reference cross-sectional areas were 
measured at the most visibly normal area (largest lumen with 
the smallest plaque burden) within 10 mm of the proximal or 
distal ends of the lesion. Minimal luminal area was defined as 
the smallest area within the target lesion. Volumes were cal-
culated using Simpson’s rule. Vessel volume was defined as 
external elastic membrane volume. Peristent plaque volume 
was calculated as vessel minus stent volume. Neointimal vol-
ume was calculated as stent minus lumen volume, and neo-
intimal obstruction was calculated as neointimal volume di-
vided by stent volume, expressed as a percentage. Vessel, 
peristent plaque, stent, lumen, and neointimal volumes were 
computed for the entire stented segment. To adjust for dif-
ferent stent lengths, the neointimal volume index was cal-
culated as neointimal volume divided by stent length.
Inflammatory biomarkers 
Blood samples were collected at baseline prior to PCI and 2 Combined Therapy of Celecoxib and Doxycycline and Neointimal Hyperplasia 
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tery variations or extremely tortuous subclavian and 
brachiocephalic artery for the insertion of guiding catheter. 
In the remaining four cases, images of IVUS were not ob-
tained because of patient’s refusal (n=2) or not analyzable 
due to poor image quality (n=2). None of these patients 
showed significant restenosis >50%. Table 4 summarizes 
the result of IVUS volumetric analysis at the target lesions. 
There were no significant differences in neointimal volume 
obstruction or neointimal hyperplasia volume index among 
the three different treatment groups. Administration of cele-
coxib with or without doxycycline did not result in reduc-
tion of neointimal hyperplasia volumes compared with con-
trol therapy at 6 months. 
Clinical events
Mean clinical follow-up duration was 191±22 days (maxi-
mum, 266 days). There were no cardiovascular deaths, non-
fatal myocardial infarctions, or stent thromboses during the 
study period. Ten patients required revascularization at the 
target lesions during the 6 months after coronary stenting. 
different at baseline (Table 1 and 2). 
Angiographic data
Follow-up angiography at 6 months was performed in 65 
patients with 73 lesions. Table 3 shows qualitative compar-
ative analysis outcomes at pre-intervention, just after coro-
nary stenting, and at 6 months follow-up. Late luminal loss 
and binary restenosis were similar among the three groups. 
The binary restenosis rate was 28% in the combination 
group, whereas 25% and 17.9% in the celecoxib-only and 
control groups, respectively (p=0.666). 
IVUS data
Follow-up IVUS data at 6 months were available for 58 pa-
tients with 65 lesions. The interval between baseline and 
follow-up studies averaged 6.6±1.4 months. Follow-up 
IVUS data were not obtained in 7 patients with 8 lesions 
who were followed with coronary angiography due to fol-
lowing reasons: IVUS could not be performed in three pa-
tients due to technical constraints such abnormal radial ar-
Table 1.  Baseline Clinical and Angiographic Characteristics
Characteristic Combination group 
(n=25) 
Celecoxib group 
(n=25)
Control group 
(n=25) p value
Age (yrs) 62±10  58±11 58±9 0.334
Male   17 (68.0%) 19 (76.0%) 20 (80.0%) 0.611
Diabetes mellitus    3 (12.0%) 1 (4.0%)   3 (12.0%) 0.532
Hypertension   14 (56.0%) 13 (54.2%) 10 (40.0%) 0.466
Current smoker   12 (48.0%) 14 (56.0%) 18 (72.0%) 0.214
Hypercholesterolemia*    5 (20.0%)   3 (12.0%)   5 (20.0%) 0.689
Clinical diagnosis
    Stable angina 11 (44.0%)   6 (24.0%)   5 (20.0%) 0.136
    Unstable angina 10 (40.0%)   9 (36.0%)   9 (36.0%) 0.945
    AMI   4 (16.0%) 10 (40.0%) 11 (44.0%) 0.076
Number of diseased vessels
    1 vessel 13 (52.0%) 11 (44.0%) 12 (48.0%) 0.852
    2 vessels   8 (32.0%) 11 (44.0%)   8 (32.0%) 0.594
    3 vessels   4 (16.0%)   3 (12.0%)   5 (20.0%) 0.743
Lipid profile
    Total cholesterol (mg/dL) 172.0±37.3 167.6±26.0 163.8±33.0 0.755
    LDL cholesterol (mg/dL) 107.5±39.2 113.8±21.6 102.7±33.6 0.360
    HDL cholesterol (mg/dL)   43.6±10.4 41.0±6.0 37.7±8.5 0.234
    Triglyceride (mg/dL) 142.2±60.0 140.4±55.0 144.1±82.4 0.905
Previous medications
   Statin   7 (28.0%)   6 (24.0%) 10 (40.0%) 0.443
   ACEI/ARB 12 (48.8%) 11 (44.0%) 11 (44.0%) 0.948
AMI, acute myocardial infarction; LDL, low density lipoprotein; HDL, high density lipoprotein; ACEI, angiotensin converting enzyme in-
hibitor; ARB, angiotensin receptor blocker.
Values are presented as n (%) or mean±SD, as appropriate. ANOVAs or Kruskal-Wallis tests were used for statistical analyses. Values 
of p<0.05 were considered statistically significant. 
*Total cholesterol >200 mg/dL. Won Ho Kim, et al.
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at baseline prior to PCI, and 48 hours and 3 weeks after 
PCI are shown in Table 5. There was a general rise in the 
blood levels of hsCRP, soluble CD40 ligand, and MMP-9 
48 hours after coronary stenting. At 3 weeks, blood levels 
of hsCRP and MMP-9 returned to (or below) baseline val-
The target lesion revascularization rate was not different 
among the three treatment groups.   
Inflammation biomarkers
Serum or plasma levels of hsCRP, CD40 ligand, and MMP-9 
Table 2.  Lesion and Procedural Characteristics 
Characteristic Combination group 
(n=26) 
Celecoxib group
(n=28)
Control group
(n=32) p value
Target vessel
    LAD   7 (26.9%)   9 (32.1%) 11 (34.4%) 0.773
    LCX   8 (30.8%)   9 (32.1%)   5 (15.6%) 0.249
    RCA 11 (42.3%) 10 (35.7%) 16 (50.0%) 0.355
Lesion type B2/C 12 (52.2%) 16 (61.5%) 13 (54.2%) 0.782
Pre-PCI
    Lesion length 19.2±4.8 19.7±5.4 19.6±5.5 0.946
    Reference diameter, mm   3.1±0.4   3.2±0.7   3.3±0.5 0.530
    Minimal lumen diameter, mm   0.8±0.4   0.8±0.4   0.9±0.4 0.550
    Diameter stenosis, %   74.2±13.6   74.3±13.6   71.6±13.1 0.734
Post-PCI
    Mean stent length, mm 21.2±4.1 21.5±4.5 21.4±4.8 0.986
    Mean stent diameter, mm   3.4±0.4   3.4±0.4   3.5±0.4 0.550
    Reference diameter, mm   3.2±0.4   3.3±0.6   3.3±0.4 0.610
    Minimal lumen diameter, mm   3.0±0.5   3.0±0.4   3.2±0.4 0.580
    Diameter stenosis, %   6.2±5.1   5.9±7.6   4.1±5.9 0.338
LAD, left anterior descending; LCX, left circumflex; RCA, right coronary artery; PCI, percutaneous coronary intervention.
Values are presented as n (%) or mean±SD, as appropriate. ANOVA or Kruskal-Wallis tests were used for statistical analyses. Values of 
p<0.05 were considered statistically significant. 
Table 3.  QCA Measurements at 6-Month Follow-Up
Variable Combination group
(n = 23)
Celecoxib group
(n = 26)
Control group
(n =24) p value
Reference diameter, mm 3.0±0.4 3.0±0.5 3.0±0.5 0.988
Minimal lumen diameter, mm 1.8±0.7 2.0±0.6 2.1±0.7 0.820
Diameter stenosis, % 38.8±22.6 30.8±20.2 30.5±20.1 0.602
Binary restenosis  7 (28%) 7 (25%) 5 (17.9%) 0.666
Acute gain, mm 3.2±4.9 2.2±0.5 2.2±0.5 0.927
Late loss, mm 2.5±5.1 1.1±0.8 1.4±1.0 0.271
QCA, qualitative comparative analysis.
Values are presented as n (%) or mean±SD, as appropriate. ANOVAs or Kruskal-Wallis tests were used for statistical analyses. Values 
of p<0.05 were considered statistically significant.
Table 4.  Volumetric Intravascular Ultrasound Measurements at 6 Months
Variable Combination group
(n=20) 
Celecoxib group
(n=23)
Control group
(n=22) p value
Vessel volume, mm
3 300.5±82.8   313.3±120.5 279.1±78.9 0.650
Stent volume, mm
3 104.1±37.4 123.7±53.9 100.5±31.9 0.425
Lumen volume, mm
3 196.3±73.3 189.6±75.6 178.6±59.1 0.896
Peristent plaque volume, mm
3 232.4±80.1  243.7±111.6 212.1±85.7 0.528
Neointimal volume, mm
3   58.1±44.1  40.7±22.4   48.9±27.2 0.420
Neointimal volume obstruction, %   33.9±20.1  23.9±18.2   32.2±14.1 0.204
Neointimal volume index   2.8±2.1   1.9± 1.4   2.3±1.5 0.436
Values are presented as n (%) or mean±SD, as appropriate. ANOVAs or Kruskal-Wallis tests were used for statistical analyses. Values 
of p<0.05 were considered statistically significant.  Combined Therapy of Celecoxib and Doxycycline and Neointimal Hyperplasia 
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of the study by Koo, et al.,10 however, the beneficial effects 
of COX-2 inhibition in coronary artery disease have not been 
consistently supported by other studies. Whereas Wang, et 
al.8 and Yang, et al.9 demonstrated that selective COX-2 in-
hibition with celecoxib led to on inhibition of neointimal 
hyperplasia in different animal models, Connolly, et al.7 re-
ported that COX-2 did not play a role in the development of 
intimal hyperplasia, despite being expressed in the neointi-
ma. Furthermore, the inhibition of COX-2 with rofecoxib 
failed to improve endothelial function in two clinical tri-
als,17,18 although Chenevard, et al.19 showed that inhibition 
of COX-2 with celecoxib achieved significant improve-
ment of endothelial function in patients with coronary ar-
tery disease. There are also conflicting data with respect to 
the anti-inflammatory effects of COX-2 inhibition. Al-
though Chenevard, et al.19 and Bogaty, et al.17 reported that 
inhibition of COX-2 led to reduced levels of inflammatory 
biomarkers, Koo, et al.10 and Title, et al.18 reported that ad-
ministration of selective COX-2 inhibitors did not signifi-
cantly change the levels of inflammatory biomarkers. These 
conflicting results might reflect the wide variation in base-
ues, whereas soluble CD40 ligand levels tended to remain 
variably elevated. However, there were no differences in 
biomarker changes at any time point among the different 
treatment groups. 
DISCUSSION
The present study shows that treatment with neither cele-
coxib alone nor with celecoxib combined with doxycyclin 
for 3 weeks reduced neointimal hyperplasia at 6 months. 
Furthermore, neither treatment was capable of reducing 
blood levels of hsCRP, soluble CD40 ligand or MMP-9 af-
ter stent implantation.  
A recently published study showed that the adjunctive 
use of celecoxib for 6 months after implantation of DES re-
duced the need for revascularization of the target lesion.10 
In addition to suppression of inflammatory reactions, inhi-
bition of injury-induced Akt activation has been suggested 
to be an important mechanism by which celecoxib prevents 
restenosis after angioplasty.9 Despite the promising results 
Table 5.  Inflammatory Marker Measurement: Comparison among the Three Groups at 1-Month Follow-Up
Marker Combination group
(n=24)
Celecoxib group
(n=25)
Control group
(n=22) p value
hsCRP
    Pre-PCI   3.0±4.8   2.5±2.7   3.5±3.7 0.653
    Post-PCI 48 hrs     9.0±10.6   14.5±20.3   11.7±13.0 0.591
    Post-PCI 3 wks   1.0±0.8   1.4±1.6   1.9±1.7 0.598
    Δ from pre-PCI to post-PCI 48 hrs     6.3±11.1   10.8±18.9     6.5±10.0 0.436
    Δ from post-PCI 48 h to 3 wks      -8.2±10.5 -13.3±20.9    -8.8±10.1 0.776
    Δ from pre-PCI to post-PCI 3 wks  -2.1±5.0 -0.8±2.4  -1.4±2.7 0.696
CD40-ligand
    Pre-PCI 1149.0±538.9 1011.0±672.7 1116.9±685.7 0.715
    Post-PCI 48 hrs 1692.7±417.7 1684.7±585.6 1493.3±458.5 0.479
    Post-PCI 3 wks 1394.9±489.7 1678.2±434.5 1567.5±630.3 0.248
    Δ from pre-PCI to post-PCI 48 hrs   647.4±659.8   820.2±970.4   674.4±513.7 0.527
    Δ from post-PCI 48 h to 3 wks  -310.7±635.0     34.4±580.4    -51.6±458.9 0.278
    Δ from pre-PCI to 3 wks   271.4±587.1   682.3±648.1   501.4±582.7 0.135
MMP-9
    Pre-PCI   5.4±3.4   5.1±3.5   3.8±2.4 0.319
    Post-PCI 48 hrs   6.8±3.1   7.3±4.5   5.0±3.1 0.261
    Post-PCI 3 wks   4.1±2.3   4.8±2.9   4.0±2.2 0.565
    Δ from pre-PCI to post-PCI 48 hrs   1.8±2.9   1.7±5.1   2.1±2.5 0.917
    Δ from post-PCI 48 h to 3 wks -2.7±3.6 -2.4±5.0  -1.4±4.3 0.484
    Δ from pre-PCI to 3 wks -1.6±4.0 -0.4±3.9   0.7±2.0 0.207
hsCRP, high sensitivity C-reactive protein; MMP-9, matrix metalloproteinase-9; PCI, percutaneous coronary intervention.
Values are presented as n (%) or mean±SD, as appropriate. ANOVAs or Kruskal-Wallis tests were used for statistical analyses. Values 
of p<0.05 were considered statistically significant.Won Ho Kim, et al.
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demonstrate any beneficial effect of COX-2 and doxycyclin 
therapy with respect to reducing the levels of inflammatory 
biomarkers or attenuating neointimal hyperplasia. Because 
there was no significant decrease in MMP-9 levels in the 
combination therapy group, we cannot rule out the possibil-
ity that the dose of doxycycline was not sufficient to sup-
press the activity of MMP-9.
There are several limitations in the present study. First, 
the number of study patients might have been small to de-
tect the difference in neointimal volume obstruction among 
the patient groups, because the neointimal volume obstruc-
tion within the same patient group showed a greater variation 
than that we have expected. Consequently, the trial might 
have inadequate statistical power to demonstrate therapeu-
tic effects of celecoxib. Second, there were varied distribu-
tions of baseline clinical characteristics among the patient 
groups because of small study population and non-stratified 
randomization procedure. Even though the differences were 
not statistically significant, we cannot rule out that they might 
have influence on the extent of NIH and restenosis rate. 
Third, the patients exhibited a wide variation in inflamma-
tory status, which added a level of complexity in evaluating 
the differences among the study groups. Finally, the time 
points chosen for evaluation of serial changes in blood lev-
els of inflammatory biomarkers may not have been optimal. 
In conclusion, our study failed to demonstrate beneficial ef-
fects of the short-term therapy with celecoxib and doxycy-
cline or with celecoxib alone in the suppression of inflamma-
tory biomarkers or in the inhibition of neointimal hyperplasia. 
Large scale randomized trials are necessary to define the role 
of anti-inflammatory therapy in the inhibition of neointimal 
hyperplasia.   
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